Showing results (51-60 of 57) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Frontiers in Pharmacology|October 1, 2024
Study on pharmacokinetic and tissue distribution of hyperin, astragalin, kaempferol-3-O-β-D-glucuronide from rats with multiple administrations of Semen Cuscutae processed with salt solution with effect of treating recurrent spontaneous abortionZhitong Yang, Kaiwen Chen, Yuting Zhang, et al.Respiratory Research|January 23, 2024
Diagnostic accuracy of thoracic CT to differentiate transudative from exudative pleural effusion prior to thoracentesisYan Zhang, Yang Zhang, Wei Wang, et al.Journal of Hematology & Oncology|August 16, 2024
Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphomaAllison Rosenthal, Javier Munoz, Monika Jun, et al.Lab on a Chip|April 11, 2022
Microscopic artificial cilia - a reviewTanveer Ul Islam, Ye Wang, Ishu Aggarwal, et al.Future Oncology (London, England)|August 13, 2025
Clinical representativeness of pivotal trials for T-cell engagers in relapsed/refractory follicular lymphomaZhijie Ding, Guihua Zhang, Junhua Yu, et al.Clinical Lymphoma, Myeloma & Leukemia|November 8, 2025
Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative AnalysisJavier Munoz, Allison Rosenthal, Andrew Ip, et al.Clinical Lymphoma, Myeloma & Leukemia|February 18, 2025
Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell LymphomaLoretta J Nastoupil, Clark R Andersen, Amy Ayers, et al.Pageof 6